Physician profile
Stanley Rossman
NPI 1578667127
$5,395.83
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,734 · 2020: $662.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $452.15 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $414.83 | 2019-2020 | |
| Genentech USA, INC. | $351.69 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $330.29 | 2019-2020 | |
| Amgen INC. | $267.96 | 2019 | |
| Alexion Pharmaceuticals, INC. | $249.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $240.83 | 2019 | |
| Seagen INC. | $240.67 | 2019-2020 | |
| Genzyme Corporation | $223.43 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $219.11 | 2019-2020 | |
| Incyte Corporation | $196.29 | 2019-2020 | |
| Janssen Biotech, INC. | $170.86 | 2019-2020 | |
| Celgene Corporation | $153.03 | 2019 | |
| Pfizer INC. | $151.80 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $150.68 | 2019-2020 |
Show all 45 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Rossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.